Bom, D and Curran, DP and Zhang, J and Zimmer, SG and Bevins, R and Kruszewski, S and Howe, JN and Bingcang, A and Latus, LJ and Burke, TG
(2001)
The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity.
Journal of Controlled Release, 74 (1-3).
325 - 333.
ISSN 0168-3659
![[img]](http://d-scholarship.pitt.edu/style/images/fileicons/text_plain.png) |
Plain Text (licence)
Available under License : See the attached license file.
Download (1kB)
|
Abstract
The novel silatecan 7-t-butyldimethylsilyl-10-hydroxycamptothecin (DB-67) is 25- to 50-times more lipophilic than camptothecin and readily incorporates into lipid bilayers. Using the method of fluorescence anisotropy titration, we determined that DB-67 bound to small unilamellar vesicles composed of dilaurylphosphatidylcholine (DLPC) with an association constant (K value) of 5000 M-1. This association constant is significantly higher than the KDLPC value observed for camptothecin (KDLPC value of 110 M-1). Using HPLC methods, we demonstrated that the presence of liposomal membranes readily stabilize the lactone form of DB-67. At drug and lipid concentrations of 10 μM and 0.3 mM, respectively, the lactone form of DB-67 persisted in liposome suspension after 3 h of incubation at 37°C. Thus an advantage of a liposomal formulation of DB-67 is that the presence of lipid bilayers assists with stabilizing the key pharmacophore of the agent. The highly lipophilic character of DB-67, in combination with its 10-hydroxy moiety (which functions to enhance lactone stability in the presence of human serum albumin), results in DB-67 having superior stability in human blood with a percent lactone at equilibrium value of 30 [Cancer Res. 59 (1999) 4898; J. Med. Chem. 43 (2000) 3970]. Potent cytotoxicities against a broad range of cancer cells were observed for DB-67, indicating that DB-67 is of comparable potency to camptothecin. The impressive human blood stability and cytotoxicity profiles for DB-67 indicate it is an excellent candidate for comprehensive in vivo pharmacological and efficacy studies. Based on these promising attributes, DB-67 is currently being developed under the NCI RAID program. Due to its potent anti-topoisomerase I activity and its intrinsic blood stability, DB-67 appears as an attractive novel camptothecin for clinical development. © 2001 Elsevier Science B.V. All rights reserved.
Share
Citation/Export: |
|
Social Networking: |
|
Details
Item Type: |
Article
|
Status: |
Published |
Creators/Authors: |
Creators | Email | Pitt Username | ORCID  |
---|
Bom, D | | | | Curran, DP | curran@pitt.edu | CURRAN | | Zhang, J | | | | Zimmer, SG | | | | Bevins, R | | | | Kruszewski, S | | | | Howe, JN | | | | Bingcang, A | | | | Latus, LJ | | | | Burke, TG | | | |
|
Date: |
6 July 2001 |
Date Type: |
Publication |
Journal or Publication Title: |
Journal of Controlled Release |
Volume: |
74 |
Number: |
1-3 |
Page Range: |
325 - 333 |
DOI or Unique Handle: |
10.1016/s0168-3659(01)00343-1 |
Schools and Programs: |
Dietrich School of Arts and Sciences > Chemistry |
Refereed: |
Yes |
ISSN: |
0168-3659 |
MeSH Headings: |
Anisotropy; Antineoplastic Agents, Phytogenic--chemistry; Antineoplastic Agents, Phytogenic--pharmacology; Camptothecin--analogs & derivatives; Camptothecin--chemistry; Camptothecin--pharmacology; Camptothecin--therapeutic use; Chemistry, Physical; Chromatography, High Pressure Liquid; Drug Screening Assays, Antitumor; Enzyme Inhibitors--chemistry; Enzyme Inhibitors--pharmacology; Humans; Lactones--blood; Lipid Bilayers; Organosilicon Compounds--chemistry; Organosilicon Compounds--pharmacology; Physicochemical Phenomena; Spectrometry, Fluorescence; Topoisomerase I Inhibitors; Tumor Cells, Cultured |
PubMed ID: |
11489514 |
Date Deposited: |
13 Feb 2014 19:24 |
Last Modified: |
22 Jun 2021 13:56 |
URI: |
http://d-scholarship.pitt.edu/id/eprint/20521 |
Metrics
Monthly Views for the past 3 years
Plum Analytics
Altmetric.com
Actions (login required)
 |
View Item |